- Home
- FHN vs CGEN Comparison
FHN vs CGEN Comparison
Compare FHN & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHN
- CGEN
- Stock Information
- Founded
- FHN 1864
- CGEN 1993
- Country
- FHN United States
- CGEN Israel
- Employees
- FHN N/A
- CGEN N/A
- Industry
- FHN Major Banks
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FHN Finance
- CGEN Health Care
- Exchange
- FHN Nasdaq
- CGEN Nasdaq
- Market Cap
- FHN 9.1B
- CGEN 167.4M
- IPO Year
- FHN N/A
- CGEN 2000
- Fundamental
- Price
- FHN $22.01
- CGEN $1.80
- Analyst Decision
- FHN Buy
- CGEN
- Analyst Count
- FHN 17
- CGEN 0
- Target Price
- FHN $22.26
- CGEN N/A
- AVG Volume (30 Days)
- FHN 5.9M
- CGEN 181.3K
- Earning Date
- FHN 07-16-2025
- CGEN 08-05-2025
- Dividend Yield
- FHN 2.76%
- CGEN N/A
- EPS Growth
- FHN N/A
- CGEN N/A
- EPS
- FHN 1.44
- CGEN N/A
- Revenue
- FHN $3,043,000,000.00
- CGEN $27,589,000.00
- Revenue This Year
- FHN $11.15
- CGEN N/A
- Revenue Next Year
- FHN $3.91
- CGEN $173.80
- P/E Ratio
- FHN $15.30
- CGEN N/A
- Revenue Growth
- FHN 3.43
- CGEN N/A
- 52 Week Low
- FHN $14.34
- CGEN $1.13
- 52 Week High
- FHN $22.44
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- FHN 74.09
- CGEN 58.50
- Support Level
- FHN $20.98
- CGEN $1.62
- Resistance Level
- FHN $20.62
- CGEN $1.81
- Average True Range (ATR)
- FHN 0.41
- CGEN 0.08
- MACD
- FHN 0.19
- CGEN -0.00
- Stochastic Oscillator
- FHN 95.35
- CGEN 69.57
About FHN First Horizon Corporation
First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The company's reportable segments are: Commercial, Consumer & Wealth, Wholesale, and Corporate. The majority of its revenue is generated from Commercial, Consumer & Wealth. The Commercial, Consumer & Wealth segment offers financial products and services, including traditional lending and deposit taking, to commercial and consumer clients in the southern USA and other selected markets.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.